image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 124.73
-12.4 %
$ 6.99 B
Market Cap
-4157.67
P/E
1. INTRINSIC VALUE

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand.[ Read More ]

The intrinsic value of one RGEN stock under the base case scenario is HIDDEN Compared to the current market price of 125 USD, Repligen Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RGEN

image
FINANCIALS
639 M REVENUE
-20.31%
54.6 M OPERATING INCOME
-59.15%
41.6 M NET INCOME
-77.64%
114 M OPERATING CASH FLOW
-33.80%
-123 M INVESTING CASH FLOW
47.15%
249 M FINANCING CASH FLOW
1966.69%
154 M REVENUE
1.80%
1.49 M OPERATING INCOME
-26.78%
3.32 M NET INCOME
58.60%
42.2 M OPERATING CASH FLOW
-5.63%
-7.4 M INVESTING CASH FLOW
11.50%
-5.77 M FINANCING CASH FLOW
35.67%
Balance Sheet Decomposition Repligen Corporation
image
Current Assets 1.11 B
Cash & Short-Term Investments 751 M
Receivables 124 M
Other Current Assets 236 M
Non-Current Assets 1.71 B
Long-Term Investments 0
PP&E 323 M
Other Non-Current Assets 1.39 B
Current Liabilities 158 M
Accounts Payable 19.6 M
Short-Term Debt 75.1 M
Other Current Liabilities 63.5 M
Non-Current Liabilities 695 M
Long-Term Debt 637 M
Other Non-Current Liabilities 58.3 M
EFFICIENCY
Earnings Waterfall Repligen Corporation
image
Revenue 639 M
Cost Of Revenue 355 M
Gross Profit 284 M
Operating Expenses 230 M
Operating Income 54.6 M
Other Expenses 13 M
Net Income 41.6 M
RATIOS
44.50% GROSS MARGIN
44.50%
8.54% OPERATING MARGIN
8.54%
6.51% NET MARGIN
6.51%
2.11% ROE
2.11%
1.47% ROA
1.47%
1.39% ROIC
1.39%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Repligen Corporation
image
Net Income 41.6 M
Depreciation & Amortization 68.1 M
Capital Expenditures -39 M
Stock-Based Compensation 25.6 M
Change in Working Capital -8.64 M
Others -51.5 M
Free Cash Flow 74.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Repligen Corporation
image
Wall Street analysts predict an average 1-year price target for RGEN of $193 , with forecasts ranging from a low of $155 to a high of $220 .
RGEN Lowest Price Target Wall Street Target
155 USD 24.27%
RGEN Average Price Target Wall Street Target
193 USD 55.05%
RGEN Highest Price Target Wall Street Target
220 USD 76.38%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Repligen Corporation
image
Sold
0-3 MONTHS
3.23 M USD 1
3-6 MONTHS
5.26 M USD 2
6-9 MONTHS
5.04 M USD 4
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
600 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Sep 10, 2024
Sell 215 K USD
Hunt Anthony
Director
- 1495
143.77 USD
2 months ago
Sep 10, 2024
Sell 1.36 M USD
Hunt Anthony
Director
- 9369
144.88 USD
2 months ago
Sep 10, 2024
Sell 1.57 M USD
Hunt Anthony
Director
- 10723
145.95 USD
2 months ago
Sep 10, 2024
Sell 88.6 K USD
Hunt Anthony
Director
- 604
146.67 USD
3 months ago
Aug 02, 2024
Sell 1.11 M USD
KURIYEL RALF
Senior VP, R&D
- 6973
159.36 USD
3 months ago
Aug 02, 2024
Sell 27.8 K USD
KURIYEL RALF
Senior VP, R&D
- 175
158.85 USD
3 months ago
Aug 01, 2024
Sell 740 K USD
KURIYEL RALF
Senior VP, R&D
- 4465
165.67 USD
5 months ago
Jun 14, 2024
Bought 87.8 K USD
Madaus Martin D
Director
+ 700
125.46 USD
5 months ago
Jun 14, 2024
Bought 114 K USD
Madaus Martin D
Director
+ 915
124.54 USD
5 months ago
Jun 14, 2024
Bought 151 K USD
BARTHELEMY NICOLAS
Director
+ 1200
125.45 USD
5 months ago
Jun 14, 2024
Bought 248 K USD
Hunt Anthony
Chief Executive Officer
+ 2000
124.08 USD
5 months ago
May 21, 2024
Sell 711 K USD
Hunt Anthony
Chief Executive Officer
- 4274
166.36 USD
5 months ago
May 21, 2024
Sell 670 K USD
Hunt Anthony
Chief Executive Officer
- 4008
167.05 USD
5 months ago
May 21, 2024
Sell 662 K USD
Hunt Anthony
Chief Executive Officer
- 3933
168.33 USD
5 months ago
May 21, 2024
Sell 502 K USD
Hunt Anthony
Chief Executive Officer
- 2963
169.27 USD
5 months ago
May 21, 2024
Sell 667 K USD
Hunt Anthony
Chief Executive Officer
- 3925
170.04 USD
5 months ago
May 21, 2024
Sell 166 K USD
Hunt Anthony
Chief Executive Officer
- 969
171.03 USD
8 months ago
Mar 11, 2024
Sell 681 K USD
KURIYEL RALF
Senior VP, R&D
- 3517
193.73 USD
8 months ago
Mar 08, 2024
Sell 660 K USD
Hunt Anthony
Chief Executive Officer
- 3377
195.49 USD
8 months ago
Mar 08, 2024
Sell 1.22 M USD
Hunt Anthony
Chief Executive Officer
- 6228
196.32 USD
8 months ago
Mar 08, 2024
Sell 329 K USD
Hunt Anthony
Chief Executive Officer
- 1666
197.39 USD
8 months ago
Mar 08, 2024
Sell 267 K USD
Hunt Anthony
Chief Executive Officer
- 1347
198.55 USD
8 months ago
Mar 08, 2024
Sell 364 K USD
Hunt Anthony
Chief Executive Officer
- 1822
199.53 USD
8 months ago
Mar 08, 2024
Sell 262 K USD
Hunt Anthony
Chief Executive Officer
- 1305
200.56 USD
8 months ago
Mar 08, 2024
Sell 163 K USD
Hunt Anthony
Chief Executive Officer
- 806
201.75 USD
8 months ago
Mar 08, 2024
Sell 31.6 K USD
Hunt Anthony
Chief Executive Officer
- 156
202.55 USD
8 months ago
Feb 27, 2024
Sell 193 K USD
DAWES KAREN A
Director
- 1000
193.35 USD
8 months ago
Feb 23, 2024
Sell 866 K USD
Bylund James
Chief Operating Officer
- 4373
198.08 USD
1 year ago
Nov 10, 2023
Sell 557 K USD
Gebski Christine
See Remarks
- 3788
147.13 USD
1 year ago
Aug 29, 2023
Sell 146 K USD
DAWES KAREN A
Director
- 850
171.38 USD
1 year ago
May 08, 2023
Bought 78.1 K USD
Madaus Martin D
Director
+ 500
156.18 USD
1 year ago
May 05, 2023
Bought 79.6 K USD
Madaus Martin D
Director
+ 500
159.19 USD
1 year ago
May 04, 2023
Bought 80.6 K USD
Madaus Martin D
Director
+ 500
161.15 USD
1 year ago
Feb 16, 2023
Sell 1.13 M USD
Snodgres Jon
Chief Financial Officer
- 5647
200 USD
2 years ago
Mar 16, 2022
Bought 109 K USD
EGLINTON MANNER CARRIE
Director
+ 625
175.02 USD
2 years ago
Nov 11, 2022
Sell 5 M USD
Hunt Anthony
Chief Executive Officer
- 25000
200 USD
2 years ago
Sep 09, 2022
Sell 176 K USD
DAWES KAREN A
director:
- 775
227.17 USD
2 years ago
Sep 08, 2022
Sell 1.49 M USD
Hunt Anthony
Chief Executive Officer
- 6626
224.47 USD
2 years ago
Aug 16, 2022
Sell 1.09 M USD
Snodgres Jon
Chief Financial Officer
- 4298
252.7 USD
2 years ago
Aug 16, 2022
Sell 608 K USD
Snodgres Jon
Chief Financial Officer
- 2400
253.16 USD
2 years ago
Aug 11, 2022
Sell 204 K USD
KURIYEL RALF
Senior VP, R&D
- 800
255.2 USD
2 years ago
Aug 11, 2022
Sell 1.03 M USD
KURIYEL RALF
Senior VP, R&D
- 4040
254.14 USD
2 years ago
Aug 04, 2022
Sell 816 K USD
Gebski Christine
See Remarks
- 3357
243.01 USD
2 years ago
Aug 03, 2022
Sell 481 K USD
Bylund James
Chief Operating Officer
- 2000
240.4 USD
2 years ago
Aug 01, 2022
Sell 440 K USD
Snodgres Jon
Chief Financial Officer
- 2000
220 USD
2 years ago
Jul 21, 2022
Sell 4.96 M USD
Hunt Anthony
Chief Executive Officer
- 24802
200 USD
2 years ago
May 25, 2022
Sell 384 K USD
DAWES KAREN A
Director
- 2576
149.18 USD
2 years ago
May 25, 2022
Sell 1.15 M USD
DAWES KAREN A
Director
- 7677
150.19 USD
2 years ago
May 25, 2022
Sell 279 K USD
DAWES KAREN A
Director
- 1845
151.14 USD
2 years ago
May 25, 2022
Sell 285 K USD
DAWES KAREN A
Director
- 1875
152.14 USD
2 years ago
May 25, 2022
Sell 113 K USD
DAWES KAREN A
director:
- 742
152.84 USD
2 years ago
Mar 01, 2022
Sell 198 K USD
RYAN THOMAS F JR
Director
- 1000
198.48 USD
2 years ago
Mar 01, 2022
Sell 198 K USD
RYAN THOMAS F JR
Director
- 1000
197.58 USD
3 years ago
Nov 18, 2021
Sell 565 K USD
Hunt Anthony
Chief Executive Officer
- 2061
273.91 USD
3 years ago
Nov 18, 2021
Sell 537 K USD
Hunt Anthony
Chief Executive Officer
- 1955
274.83 USD
3 years ago
Nov 18, 2021
Sell 1.11 M USD
Hunt Anthony
Chief Executive Officer
- 4017
276.2 USD
3 years ago
Nov 18, 2021
Sell 480 K USD
Hunt Anthony
Chief Executive Officer
- 1732
277.01 USD
3 years ago
Nov 18, 2021
Sell 1.68 M USD
Hunt Anthony
Chief Executive Officer
- 6024
278.08 USD
3 years ago
Nov 18, 2021
Sell 271 K USD
Hunt Anthony
Chief Executive Officer
- 970
279.08 USD
3 years ago
Nov 18, 2021
Sell 168 K USD
Hunt Anthony
Chief Executive Officer
- 596
281.4 USD
3 years ago
Nov 10, 2021
Sell 120 K USD
DAWES KAREN A
Director
- 462
259.75 USD
3 years ago
Nov 10, 2021
Sell 61.6 K USD
DAWES KAREN A
Director
- 236
261.1 USD
3 years ago
Nov 10, 2021
Sell 272 K USD
DAWES KAREN A
Director
- 1038
262.28 USD
3 years ago
Nov 10, 2021
Sell 295 K USD
DAWES KAREN A
Director
- 1119
263.23 USD
3 years ago
Nov 10, 2021
Sell 88.8 K USD
DAWES KAREN A
Director
- 336
264.21 USD
3 years ago
Nov 10, 2021
Sell 129 K USD
DAWES KAREN A
Director
- 488
265.27 USD
3 years ago
Nov 10, 2021
Sell 130 K USD
DAWES KAREN A
Director
- 486
266.72 USD
3 years ago
Nov 10, 2021
Sell 93.4 K USD
DAWES KAREN A
Director
- 349
267.75 USD
3 years ago
Nov 10, 2021
Sell 68.8 K USD
DAWES KAREN A
Director
- 255
269.94 USD
3 years ago
Nov 10, 2021
Sell 3.8 K USD
DAWES KAREN A
Director
- 14
271.28 USD
3 years ago
Nov 02, 2021
Sell 388 K USD
RYAN THOMAS F JR
Director
- 1285
302 USD
3 years ago
Nov 04, 2021
Sell 288 K USD
RYAN THOMAS F JR
Director
- 1000
288 USD
3 years ago
Nov 02, 2021
Sell 19.1 K USD
DAWES KAREN A
Director
- 64
299.02 USD
3 years ago
Nov 02, 2021
Sell 75.6 K USD
DAWES KAREN A
Director
- 251
301.2 USD
3 years ago
Nov 02, 2021
Sell 135 K USD
DAWES KAREN A
Director
- 446
301.97 USD
3 years ago
Nov 02, 2021
Sell 161 K USD
DAWES KAREN A
Director
- 532
303.48 USD
3 years ago
Nov 02, 2021
Sell 37.7 K USD
DAWES KAREN A
Director
- 124
304.23 USD
3 years ago
Nov 02, 2021
Sell 214 K USD
DAWES KAREN A
Director
- 700
305.91 USD
3 years ago
Nov 02, 2021
Sell 86.7 K USD
DAWES KAREN A
Director
- 283
306.49 USD
3 years ago
Oct 29, 2021
Sell 370 K USD
BARTHELEMY NICOLAS
Director
- 1285
288.2 USD
3 years ago
Oct 29, 2021
Sell 104 K USD
BARTHELEMY NICOLAS
Director
- 360
288.19 USD
3 years ago
Sep 14, 2021
Sell 3.77 K USD
DAWES KAREN A
Director
- 13
290.02 USD
3 years ago
Sep 14, 2021
Sell 7.31 K USD
DAWES KAREN A
Director
- 25
292.34 USD
3 years ago
Sep 14, 2021
Sell 29.7 K USD
DAWES KAREN A
Director
- 101
294.06 USD
3 years ago
Sep 14, 2021
Sell 31.9 K USD
DAWES KAREN A
Director
- 108
295.02 USD
3 years ago
Sep 14, 2021
Sell 7.99 K USD
DAWES KAREN A
Director
- 27
295.82 USD
3 years ago
Sep 09, 2021
Sell 2.51 M USD
Hunt Anthony
Chief Executive Officer
- 8536
294.22 USD
3 years ago
Sep 09, 2021
Sell 4.37 M USD
Hunt Anthony
Chief Executive Officer
- 14825
294.9 USD
3 years ago
Sep 09, 2021
Sell 483 K USD
Hunt Anthony
Chief Executive Officer
- 1631
296.09 USD
3 years ago
Sep 09, 2021
Sell 2.37 K USD
Hunt Anthony
Chief Executive Officer
- 8
296.58 USD
3 years ago
Sep 01, 2021
Sell 964 K USD
Gebski Christine
See Remarks
- 3377
285.33 USD
3 years ago
Sep 01, 2021
Sell 67 K USD
DAWES KAREN A
Director
- 239
280.27 USD
3 years ago
Sep 01, 2021
Sell 55.2 K USD
DAWES KAREN A
Director
- 196
281.68 USD
3 years ago
Sep 01, 2021
Sell 114 K USD
DAWES KAREN A
Director
- 405
282.53 USD
3 years ago
Sep 01, 2021
Sell 187 K USD
DAWES KAREN A
Director
- 661
283.56 USD
3 years ago
Sep 01, 2021
Sell 315 K USD
DAWES KAREN A
Director
- 1107
284.64 USD
3 years ago
Sep 01, 2021
Sell 243 K USD
DAWES KAREN A
Director
- 851
285.44 USD
3 years ago
Aug 30, 2021
Sell 1.13 M USD
KURIYEL RALF
Senior VP, R&D
- 4001
282.13 USD
3 years ago
Aug 17, 2021
Sell 232 K USD
DAWES KAREN A
Director
- 924
251.15 USD
3 years ago
Aug 17, 2021
Sell 232 K USD
DAWES KAREN A
Director
- 920
251.92 USD
3 years ago
Aug 17, 2021
Sell 1.18 M USD
DAWES KAREN A
Director
- 4665
253.34 USD
3 years ago
Aug 17, 2021
Sell 2.18 M USD
DAWES KAREN A
Director
- 8580
254.09 USD
3 years ago
Aug 17, 2021
Sell 569 K USD
DAWES KAREN A
Director
- 2231
255.07 USD
3 years ago
Aug 17, 2021
Sell 49.7 K USD
DAWES KAREN A
Director
- 194
256.43 USD
3 years ago
Aug 18, 2021
Sell 77.8 K USD
DAWES KAREN A
Director
- 302
257.66 USD
3 years ago
Aug 18, 2021
Sell 164 K USD
DAWES KAREN A
Director
- 634
258.91 USD
3 years ago
Aug 18, 2021
Sell 101 K USD
DAWES KAREN A
Director
- 388
259.93 USD
3 years ago
Aug 18, 2021
Sell 20.4 K USD
DAWES KAREN A
Director
- 78
260.91 USD
3 years ago
Aug 18, 2021
Sell 10.5 K USD
DAWES KAREN A
Director
- 40
262.31 USD
3 years ago
Aug 04, 2021
Sell 195 K USD
RYAN THOMAS F JR
Director
- 780
250.5 USD
3 years ago
Jul 20, 2021
Sell 57.6 K USD
DAWES KAREN A
Director
- 288
200.01 USD
3 years ago
Jul 20, 2021
Sell 162 K USD
DAWES KAREN A
Director
- 806
201.37 USD
3 years ago
Jul 20, 2021
Sell 582 K USD
DAWES KAREN A
Director
- 2877
202.29 USD
3 years ago
Jul 20, 2021
Sell 125 K USD
DAWES KAREN A
Director
- 614
203.11 USD
3 years ago
Jul 13, 2021
Sell 88.8 K USD
DAWES KAREN A
Director
- 441
201.27 USD
3 years ago
Jul 13, 2021
Sell 127 K USD
DAWES KAREN A
Director
- 630
202.29 USD
3 years ago
Jul 13, 2021
Sell 90.2 K USD
DAWES KAREN A
Director
- 444
203.09 USD
3 years ago
Jul 13, 2021
Sell 1.02 K USD
DAWES KAREN A
Director
- 5
204.02 USD
3 years ago
Jul 13, 2021
Sell 307 K USD
DAWES KAREN A
Director
- 1520
202.23 USD
3 years ago
Jun 10, 2021
Sell 1.29 M USD
KURIYEL RALF
Senior VP, R&D
- 6802
189.19 USD
3 years ago
May 19, 2021
Sell 103 K USD
Hunt Anthony
Chief Executive Officer
- 612
168.29 USD
3 years ago
May 19, 2021
Sell 429 K USD
Hunt Anthony
Chief Executive Officer
- 2529
169.45 USD
3 years ago
May 19, 2021
Sell 1.35 M USD
Hunt Anthony
Chief Executive Officer
- 7911
170.28 USD
3 years ago
May 19, 2021
Sell 586 K USD
Hunt Anthony
Chief Executive Officer
- 3420
171.32 USD
3 years ago
May 19, 2021
Sell 524 K USD
Hunt Anthony
Chief Executive Officer
- 3036
172.52 USD
3 years ago
May 19, 2021
Sell 270 K USD
Hunt Anthony
Chief Executive Officer
- 1560
173.19 USD
3 years ago
May 19, 2021
Sell 492 K USD
Hunt Anthony
Chief Executive Officer
- 2819
174.41 USD
3 years ago
May 19, 2021
Sell 66.6 K USD
Hunt Anthony
Chief Executive Officer
- 380
175.15 USD
3 years ago
May 14, 2021
Sell 76.7 K USD
Gebski Christine
See Remarks
- 445
172.25 USD
3 years ago
May 14, 2021
Sell 122 K USD
KURIYEL RALF
Senior VP, R&D
- 710
172.29 USD
3 years ago
May 14, 2021
Sell 81.1 K USD
Snodgres Jon
Chief Financial Officer
- 470
172.6 USD
3 years ago
May 11, 2021
Sell 50.4 K USD
DAWES KAREN A
Director
- 285
176.85 USD
3 years ago
Apr 06, 2021
Sell 73.5 K USD
Bylund James
SVP, Global Operations & IT
- 360
204.25 USD
3 years ago
Mar 16, 2021
Sell 276 K USD
Gebski Christine
See Remarks
- 1400
196.88 USD
3 years ago
Mar 12, 2021
Sell 172 K USD
Hunt Anthony
Chief Executive Officer
- 914
188.06 USD
3 years ago
Mar 12, 2021
Sell 221 K USD
Hunt Anthony
Chief Executive Officer
- 1171
188.77 USD
3 years ago
Mar 12, 2021
Sell 779 K USD
Hunt Anthony
Chief Executive Officer
- 4096
190.17 USD
3 years ago
Mar 12, 2021
Sell 207 K USD
Hunt Anthony
Chief Executive Officer
- 1081
191.19 USD
3 years ago
Mar 12, 2021
Sell 265 K USD
Hunt Anthony
Chief Executive Officer
- 1378
192.17 USD
3 years ago
Mar 12, 2021
Sell 43.9 K USD
Hunt Anthony
Chief Executive Officer
- 227
193.3 USD
3 years ago
Mar 12, 2021
Sell 45.6 K USD
Hunt Anthony
Chief Executive Officer
- 235
194.08 USD
3 years ago
Mar 10, 2021
Sell 1.21 M USD
KURIYEL RALF
Senior VP, R&D
- 6354
190.08 USD
3 years ago
Mar 10, 2021
Sell 123 K USD
KURIYEL RALF
Senior VP, R&D
- 642
191.33 USD
3 years ago
Mar 10, 2021
Sell 193 K USD
KURIYEL RALF
Senior VP, R&D
- 1004
192.13 USD
3 years ago
Mar 04, 2021
Sell 157 K USD
Hunt Anthony
Chief Executive Officer
- 794
197.94 USD
3 years ago
Mar 04, 2021
Sell 90.6 K USD
Hunt Anthony
Chief Executive Officer
- 461
196.44 USD
3 years ago
Mar 04, 2021
Sell 212 K USD
Hunt Anthony
Chief Executive Officer
- 1082
195.54 USD
3 years ago
Mar 04, 2021
Sell 413 K USD
Hunt Anthony
Chief Executive Officer
- 2125
194.43 USD
3 years ago
Mar 04, 2021
Sell 1.2 M USD
Hunt Anthony
Chief Executive Officer
- 6193
193.45 USD
3 years ago
Mar 04, 2021
Sell 112 K USD
Hunt Anthony
Chief Executive Officer
- 595
187.48 USD
3 years ago
Mar 04, 2021
Sell 798 K USD
Hunt Anthony
Chief Executive Officer
- 4271
186.9 USD
3 years ago
Mar 04, 2021
Sell 882 K USD
Hunt Anthony
Chief Executive Officer
- 4746
185.91 USD
3 years ago
Mar 04, 2021
Sell 302 K USD
Hunt Anthony
Chief Executive Officer
- 1633
185.22 USD
3 years ago
Mar 04, 2021
Sell 39.6 K USD
Snodgres Jon
Chief Financial Officer
- 200
197.86 USD
3 years ago
Mar 04, 2021
Sell 98.2 K USD
Snodgres Jon
Chief Financial Officer
- 500
196.3 USD
3 years ago
Mar 04, 2021
Sell 46.9 K USD
Snodgres Jon
Chief Financial Officer
- 242
193.72 USD
3 years ago
Mar 04, 2021
Sell 173 K USD
Snodgres Jon
Chief Financial Officer
- 900
192.54 USD
3 years ago
Mar 04, 2021
Sell 95.7 K USD
Snodgres Jon
Chief Financial Officer
- 500
191.43 USD
3 years ago
Mar 04, 2021
Sell 115 K USD
Snodgres Jon
Chief Financial Officer
- 603
190.45 USD
3 years ago
Mar 04, 2021
Sell 114 K USD
Snodgres Jon
Chief Financial Officer
- 600
189.75 USD
3 years ago
Mar 04, 2021
Sell 78.5 K USD
KURIYEL RALF
Senior VP, R&D
- 400
196.23 USD
3 years ago
Mar 04, 2021
Sell 4.86 K USD
KURIYEL RALF
Senior VP, R&D
- 25
194.3 USD
3 years ago
Mar 04, 2021
Sell 67.3 K USD
KURIYEL RALF
Senior VP, R&D
- 350
192.24 USD
3 years ago
Mar 04, 2021
Sell 115 K USD
KURIYEL RALF
Senior VP, R&D
- 600
191.2 USD
3 years ago
Mar 04, 2021
Sell 133 K USD
KURIYEL RALF
Senior VP, R&D
- 700
190.06 USD
3 years ago
Mar 03, 2021
Sell 205 K USD
RYAN THOMAS F JR
Director
- 1000
205 USD
3 years ago
Jan 04, 2021
Sell 124 K USD
Snodgres Jon
Chief Financial Officer
- 656
188.69 USD
3 years ago
Jan 04, 2021
Sell 253 K USD
Snodgres Jon
Chief Financial Officer
- 1333
190.09 USD
3 years ago
Jan 04, 2021
Sell 38.5 K USD
Snodgres Jon
Chief Financial Officer
- 202
190.5 USD
3 years ago
Jan 04, 2021
Sell 177 K USD
Snodgres Jon
Chief Financial Officer
- 918
192.74 USD
3 years ago
Jan 04, 2021
Sell 42.3 K USD
Snodgres Jon
Chief Financial Officer
- 218
193.88 USD
3 years ago
Jan 04, 2021
Sell 111 K USD
Snodgres Jon
Chief Financial Officer
- 571
195.16 USD
3 years ago
Jan 04, 2021
Sell 11.6 K USD
Snodgres Jon
Chief Financial Officer
- 59
195.77 USD
3 years ago
Dec 16, 2020
Sell 81 K USD
KURIYEL RALF
Senior VP, R&D
- 435
186.18 USD
3 years ago
Nov 19, 2020
Sell 1.01 M USD
Hunt Anthony
Chief Executive Officer
- 5447
184.69 USD
3 years ago
Nov 19, 2020
Sell 1.27 M USD
Hunt Anthony
Chief Executive Officer
- 6823
185.67 USD
3 years ago
Nov 19, 2020
Sell 1.17 M USD
Hunt Anthony
Chief Executive Officer
- 6300
186.5 USD
3 years ago
Nov 19, 2020
Sell 268 K USD
Hunt Anthony
Chief Executive Officer
- 1430
187.6 USD
4 years ago
Nov 11, 2020
Sell 175 K USD
RYAN THOMAS F JR
Director
- 934
187.73 USD
4 years ago
Nov 09, 2020
Sell 237 K USD
BARTHELEMY NICOLAS
Director
- 1214
195.51 USD
4 years ago
Nov 09, 2020
Sell 237 K USD
BARTHELEMY NICOLAS
Director
- 1214
195.51 USD
4 years ago
Nov 10, 2020
Sell 596 K USD
Snodgres Jon
Chief Financial Officer
- 3086
193 USD
4 years ago
Nov 09, 2020
Sell 137 K USD
Snodgres Jon
Chief Financial Officer
- 705
194.69 USD
4 years ago
Sep 10, 2020
Sell 713 K USD
Hunt Anthony
Chief Executive Officer
- 4856
146.85 USD
4 years ago
Sep 10, 2020
Sell 1.64 M USD
Hunt Anthony
Chief Executive Officer
- 11132
147.68 USD
4 years ago
Sep 10, 2020
Sell 4.01 M USD
Hunt Anthony
Chief Executive Officer
- 26966
148.56 USD
4 years ago
Sep 10, 2020
Sell 358 K USD
Hunt Anthony
Chief Executive Officer
- 2397
149.3 USD
4 years ago
Aug 06, 2020
Sell 769 K USD
KURIYEL RALF
Senior VP, R&D
- 5000
153.79 USD
4 years ago
Jul 31, 2020
Sell 320 K USD
RYAN THOMAS F JR
Director
- 2109
151.96 USD
4 years ago
Jul 31, 2020
Sell 150 K USD
RYAN THOMAS F JR
Director
- 986
151.77 USD
4 years ago
Jun 18, 2020
Sell 304 K USD
DAWES KAREN A
Director
- 2677
113.58 USD
4 years ago
Jun 18, 2020
Sell 600 K USD
DAWES KAREN A
Director
- 5243
114.49 USD
4 years ago
Jun 18, 2020
Sell 951 K USD
DAWES KAREN A
Director
- 8217
115.76 USD
4 years ago
Jun 18, 2020
Sell 299 K USD
DAWES KAREN A
Director
- 2568
116.56 USD
4 years ago
May 21, 2020
Sell 2.3 M USD
Hunt Anthony
Chief Executive Officer
- 16496
139.17 USD
4 years ago
May 21, 2020
Sell 4.06 M USD
Hunt Anthony
Chief Executive Officer
- 28980
140.04 USD
4 years ago
May 21, 2020
Sell 194 K USD
Hunt Anthony
Chief Executive Officer
- 1377
140.99 USD
4 years ago
May 21, 2020
Sell 14.2 K USD
Hunt Anthony
Chief Executive Officer
- 100
141.58 USD
4 years ago
May 18, 2020
Sell 429 K USD
BARTHELEMY NICOLAS
Director
- 3009
142.53 USD
4 years ago
May 20, 2020
Sell 1.36 K USD
DAWES KAREN A
Director
- 10
135.91 USD
4 years ago
May 20, 2020
Sell 5.89 K USD
DAWES KAREN A
Director
- 43
136.98 USD
4 years ago
May 20, 2020
Sell 39.3 K USD
DAWES KAREN A
Director
- 282
139.4 USD
4 years ago
May 20, 2020
Sell 25.5 K USD
DAWES KAREN A
Director
- 182
140.29 USD
4 years ago
May 18, 2020
Sell 96.7 K USD
DAWES KAREN A
Director
- 712
135.76 USD
4 years ago
May 18, 2020
Sell 21.9 K USD
DAWES KAREN A
Director
- 160
136.92 USD
4 years ago
May 18, 2020
Sell 37.3 K USD
DAWES KAREN A
Director
- 269
138.6 USD
4 years ago
May 18, 2020
Sell 17 K USD
DAWES KAREN A
Director
- 122
139.32 USD
4 years ago
May 18, 2020
Sell 25.3 K USD
DAWES KAREN A
Director
- 180
140.62 USD
4 years ago
May 18, 2020
Sell 10.9 K USD
DAWES KAREN A
Director
- 77
141.45 USD
4 years ago
May 18, 2020
Sell 11.4 K USD
DAWES KAREN A
Director
- 80
142.45 USD
4 years ago
Apr 20, 2020
Sell 336 K USD
DAWES KAREN A
Director
- 3202
104.98 USD
4 years ago
Apr 20, 2020
Sell 940 K USD
DAWES KAREN A
Director
- 8998
104.42 USD
4 years ago
May 15, 2020
Sell 61.2 K USD
KURIYEL RALF
Senior VP, R&D
- 435
140.69 USD
4 years ago
May 15, 2020
Sell 92.7 K USD
Snodgres Jon
Chief Financial Officer
- 660
140.43 USD
4 years ago
May 18, 2020
Sell 96.7 K USD
DAWES KAREN A
Director
- 712
135.76 USD
4 years ago
May 18, 2020
Sell 21.9 K USD
DAWES KAREN A
Director
- 160
136.92 USD
4 years ago
May 18, 2020
Sell 37.3 K USD
DAWES KAREN A
Director
- 269
138.6 USD
4 years ago
May 18, 2020
Sell 17 K USD
DAWES KAREN A
Director
- 122
139.32 USD
4 years ago
May 18, 2020
Sell 25.3 K USD
DAWES KAREN A
Director
- 180
140.62 USD
4 years ago
May 18, 2020
Sell 10.9 K USD
DAWES KAREN A
Director
- 77
141.45 USD
4 years ago
May 18, 2020
Sell 11.4 K USD
DAWES KAREN A
Director
- 80
142.45 USD
4 years ago
May 13, 2020
Sell 679 K USD
Snodgres Jon
Chief Financial Officer
- 5358
126.77 USD
4 years ago
May 13, 2020
Sell 366 K USD
Snodgres Jon
Chief Financial Officer
- 2865
127.75 USD
4 years ago
May 13, 2020
Sell 207 K USD
Snodgres Jon
Chief Financial Officer
- 1612
128.7 USD
4 years ago
May 13, 2020
Sell 221 K USD
Snodgres Jon
Chief Financial Officer
- 1700
130.2 USD
4 years ago
May 13, 2020
Sell 396 K USD
Snodgres Jon
Chief Financial Officer
- 3013
131.38 USD
4 years ago
May 13, 2020
Sell 112 K USD
Snodgres Jon
Chief Financial Officer
- 846
132.37 USD
4 years ago
May 13, 2020
Sell 205 K USD
KURIYEL RALF
Senior VP, R&D
- 1612
126.88 USD
4 years ago
May 13, 2020
Sell 806 K USD
KURIYEL RALF
Senior VP, R&D
- 6293
128.02 USD
4 years ago
May 13, 2020
Sell 12.2 K USD
KURIYEL RALF
Senior VP, R&D
- 95
128.55 USD
4 years ago
Apr 22, 2020
Sell 296 K USD
BARTHELEMY NICOLAS
Director
- 2688
109.99 USD
4 years ago
Apr 20, 2020
Sell 336 K USD
DAWES KAREN A
Director
- 3202
104.98 USD
4 years ago
Apr 20, 2020
Sell 940 K USD
DAWES KAREN A
Director
- 8998
104.42 USD
4 years ago
Apr 03, 2020
Sell 269 K USD
BARTHELEMY NICOLAS
Director
- 2688
99.99 USD
4 years ago
Mar 24, 2020
Sell 180 K USD
Cox John
Director
- 1858
96.72 USD
4 years ago
Mar 18, 2020
Sell 2.33 M USD
Cox John
Director
- 24533
95.13 USD
4 years ago
Mar 18, 2020
Sell 114 K USD
Cox John
Director
- 1187
96.45 USD
4 years ago
Mar 18, 2020
Sell 98.7 K USD
Cox John
Director
- 1016
97.17 USD
4 years ago
Mar 16, 2020
Sell 91.5 K USD
RYAN THOMAS F JR
Director
- 1000
91.48 USD
4 years ago
Mar 03, 2020
Sell 53.8 K USD
Snodgres Jon
Chief Financial Officer
- 610
88.18 USD
4 years ago
Mar 04, 2020
Sell 94.5 K USD
Snodgres Jon
Chief Financial Officer
- 1045
90.39 USD
7. News
Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript Repligen Corporation (NASDAQ:RGEN ) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Evan Stock - Wells Fargo Matthew Hewitt - Craig-Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Matt Stanton - Jefferies LLC Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's Third Quarter of 2024 Earnings Conference Call. seekingalpha.com - 4 days ago
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS. zacks.com - 4 days ago
Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. benzinga.com - 4 days ago
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. zacks.com - 4 days ago
Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects Repligen Corporation is a bioprocessing technology company focusing on process intensification, purification, and fluid management, with strategic acquisitions to enhance its capabilities. Though integration risks remain, RGEN's recent acquisition of Tantti Laboratory aims to bolster its chromatography and biomolecule purification capacities. The potential acquisition of Maravai LifeSciences could impact RGEN's future growth, but past failed attempts and divestment plans add uncertainty. seekingalpha.com - 5 days ago
Repligen Corporation to Present at Upcoming Investor Conferences WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. globenewswire.com - 1 week ago
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Peptide Therapeutics Industry Report 2024, Featuring Profiles of 30+ Leading Players Including PeptiDream, PolyPeptide, Repligen, X-GEN Pharmaceuticals, Zydus Cadila and More Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Peptide Therapeutics was estimated at US$42.1 Billion in 2023 and is projected to reach US$56.2 Billion by 2030, growing at a CAGR of 4.2% from 2023 to 2030. The development of peptide therapeutics has been greatly accelerated by technological advances, enabling the creation of more stable, potent, and targeted therapies. Peptides, which are naturally occurring biological molecules, serve as signaling agents in the body and have high specificity for their targets, making them attractive candidates for therapeutic development. Innovations in peptide engineering have led to the development of modified peptides that resist enzymatic degradation, improve bioavailability, and have extended half-lives, allowing for less frequent dosing. globenewswire.com - 1 month ago
Repligen Opens Training & Innovation Center to Elevate Customer Experience WALTHAM, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its Repligen Training & Innovation Center (“RTIC”) at its Waltham headquarters. globenewswire.com - 1 month ago
Repligen Corporation to Present at Wells Fargo Healthcare Conference WALTHAM, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6, at 8:45 a.m. ET. globenewswire.com - 2 months ago
Exclusive: Repligen in bid for reagent vendor Maravai, sources say Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday. reuters.com - 3 months ago
Here's Why Shares in This Hot Healthcare Stock Surged This Week A far larger peer backs up Repligen's market commentary. Bioprocessing customers are working through inventory, and orders growth is bouncing back. fool.com - 3 months ago
8. Profile Summary

Repligen Corporation RGEN

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 6.99 B
Dividend Yield 0.00%
Description Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Contact Building 1, Waltham, MA, 02453 https://www.repligen.com
IPO Date April 29, 1986
Employees 1783
Officers Mr. Anthony J. Hunt Executive Chair Ms. Kimberly A. Cornwell Global Head of Legal Mr. Neil Whitfield Vice President & Global Head of Sales Mr. Jason K. Garland Chief Financial Officer & Chief Compliance Officer Ms. Leslie Galvin Vice President of Human Resources Ms. Sondra S. Newman Global Head of Investor Relations Mr. James R. Bylund Chief Operating Officer Mr. Keith Lee Robinson Chief Information Officer Mr. Olivier Loeillot President, Chief Executive Officer & Director Mr. Ralf Kuriyel Senior Vice President of Research & Development